Furthermore, a dual agonist GLP-1/gastric inhibitory polypeptide (GIP) RA named tirzepatide has recently been approved in several countries for the treatment of diabetes and is being considered for approval for obesity and weight management.2 Here, GIP is linked to obesity disorder.